Association Between Matrix Metalloproteinase-2 Gene Polymorphism rs243865 and Susceptibility to Cataract Development
Key facts
- Who runs it
- Sohag University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 90 people enrolled
- Started
- 1 Jul 2023
- Ended
- 30 Apr 2024
- Type of study
- Observational, 3 groups
- Treatments tested
- genotyping assay by real-time PCR
- ELISA
- Record updated
- 23 July 2024
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Group A (control group) will include 30 eyes of 30 normal healthy non-cataractous volunteers aged ≥21 years. Group B (experimental group 1) will include 30 eyes of 30 cataractous patients aged >50 years and diagnosed with senile cataract. Group C (experimental group 2) will include 30 eyes of 30 cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract. The control group will include participants who will be age-matched and sex-matched with the patients in the experimental groups
Who cannot take part
- concomitant eye pathology or inflammation, systemic diseases and previous eye or systemic surgery
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary aim of this study is to investigate the potential association between MMP-2 gene polymorphism and susceptibility to cataract development in Egyptian patients. Furthermore, this study aims to compare between cataract patients and healthy controls by measuring the serum IL-6 concentration to evaluate its relationship with disease.
The 3 groups in the trial
- control group (GroupA)
normal healthy non-cataractous volunteers aged ≥21 years
Treatment: genotyping assay by real-time PCR and ELISA
- Group B (experimental group 1)
cataractous patients aged \>50 years and diagnosed with senile cataract.
Treatment: genotyping assay by real-time PCR and ELISA
- Group C (experimental group 2)
cataractous patients aged ≥21 to 50 years and diagnosed with secondary cataract
Treatment: genotyping assay by real-time PCR and ELISA
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 July 2024